CDKN2A and cancer: Moreover, high prevalence of TP53 and CDKN2A co-inactivation has been identified in a variety of cancers, including glioblastoma, hepatocellular carcinoma, lung cancer, pancreatic cancer, bladder cancer, and triple-negative breast cancer (TNBC) among others (Cerami et al., 2012; Gao et al., 2013).